SCHEMBL26428995

SCHEMBL26428995

NC(=O)c1cncc(N2CCCC2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 7/20 0.76
CHRNA4 P43681 7/20 0.76
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
SIRT2 Q8IXJ6 2/20 0.45
SIRT1 Q96EB6 2/20 0.45
SIRT3 Q9NTG7 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30811630 1.00 CHRNB2 (0.76) CHRNB2CHRNA4MKNK1MKNK2SIRT2
Hydrochloric Acid SCHEMBL30811795 0.98 CHRNB2 (0.74) CHRNB2CHRNA4MKNK1MKNK2SIRT2
SCHEMBL30811825 0.98 CHRNB2 (0.74) CHRNB2CHRNA4MKNK1MKNK2SIRT2
SCHEMBL30837593 0.97 CHRNB2 (0.76) CHRNB2CHRNA4MKNK1MKNK2SIRT2
SCHEMBL30837687 0.89 CHRNB2 (0.62) CHRNB2CHRNA4MKNK1MKNK2SIRT2
SCHEMBL20206172 0.87 CHRNB2 (0.63) CHRNB2CHRNA4MKNK1MKNK2MEN1
SCHEMBL28315377 0.85 CHRNB2 (0.62) CHRNB2CHRNA4NPC1TP53RAB9A
SCHEMBL5593185 0.84 ALDH1A1 (0.57) CHRNB2CHRNA4MEN1KMT2ANPC1
SCHEMBL23009361 0.83 CHRNB2 (0.60) CHRNB2CHRNA4MKNK1MKNK2SIRT2
SCHEMBL3941724 0.83 KDM4E (0.56) CHRNB2CHRNA4MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4582422-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-03 US disclosed
WO-2024056099-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京华益健康药物研究中心 2024-03-21 WO disclosed
CN-117720533-A MetTL3 inhibitor compound and pharmaceutical composition and application thereof 北京华益健康药物研究中心 2024-03-19 CN disclosed
WO-2023066834-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214997-A1 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF METTL3, METTL14, METTL16 CHRNB2 4468/4885CHRNA4 4400/4885MKNK1 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.